Nuvalent (NUVL) is down roughly 4% in Friday trading (April 10, 2026) after a catalyst-heavy week that included the company’s April 7 announcement that it submitted a New Drug Application (NDA) to the FDA for neladalkib in TKI pre-treated advanced ALK-positive non-small cell lung cancer. With the headline now digested and no fresh company update surfacing Friday, trading action is consistent with profit-taking and de-risking rather than a new fundamental negative development.

An NDA submission can pull forward expectations for a formal FDA review timeline, but it can also trigger “sell-the-news” behavior once the event hits—especially in biotech, where volatility often rises around regulatory milestones. Friday’s slide suggests investors are rotating out after the filing milestone, while awaiting the next concrete regulatory signal (FDA acceptance and an action date) and additional clinical updates.

Near-term attention will likely center on whether and when the FDA accepts the neladalkib filing and communicates a review timeline. Separately, investors will continue tracking Nuvalent’s broader precision-oncology pipeline milestones and any upcoming scientific conference disclosures that could shift expectations for efficacy, safety, and eventual commercial positioning.